| Next 10 |
Ad
NVO Articles Novo Nordisk A/S
home / stock / nvo / nvo articles
Articles | Novo Nordisk A/S (NYSE:NVO)
-
The skyrocketing demand for GLP-1 medications for weight loss is causing significant supply issues, often leaving type 2 diabetic patients without ...
-
On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight mana...
-
The famed Danish drug maker Novo Nordisk A/S (NYSE:NVO) expressed disappointment on Wednesday following a recommendation by the Dutch Health Care I...
-
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stock...
-
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 8.54% on an annualized basis producing an average annual return of 19...
-
Democratic U.S. Senate aides will meet with executives from Novo Nordisk A/S (NYSE:NVO) on Tuesday to discuss the ramifications of the company̵...
-
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial bu...
-
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of...
-
On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S’s (NYSE:NVO) Wegovy, to info...
Stock Information
Get NVO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2024-12-13 05:03:00 ET Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations. Investing in a stock at a steep premium can limit the return you can earn from it, or worse, result in a significant loss in the event of slowing marke...
-
2024-12-10 04:10:00 ET One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss. The weight loss drug mar...
-
2024-12-09 04:59:00 ET According to a sneak peek of the data from one of Eli Lilly 's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk , (NYSE: NVO) and it...